LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Novartis AG

Novartis AG

Затворен

116.68 0.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

116.6

Максимум

116.9

Ключови измерители
By Trading Economics
Приходи	2.7B
Продажби	344M 12B
P/E Средно за сектора	23.59 103.001
EPS	1.31
Марж на печалбата	22.178
EBITDA	4.7B

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+0.35 upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	818M 247B
Предишно отваряне	116.52
Предишно затваряне	116.68

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

116.33 / 119.15 Подкрепа & съпротива

Novartis AG Графика

Свързани новини

26.08.2024 г., 09:47 ч. UTC

Придобивния, сливания и поглъщания

Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers

18.07.2024 г., 05:58 ч. UTC

Печалби

Novartis Raises Profit Guidance as Key Drugs Boost Sales -- Update

18.07.2024 г., 05:42 ч. UTC

Печалби

Novartis Raises Profit Guidance as Key Drugs Boost Sales

5.06.2024 г., 15:26 ч. UTC

Придобивния, сливания и поглъщания

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

3.09.2024 г., 14:07 ч. UTC

Пазарно говорене

Novartis Has a Strong Drug Pipeline But Investor Optimism Is Yet to Grow -- Market Talk

19.08.2024 г., 13:36 ч. UTC

Пазарно говорене

Novartis Well on Track to Achieve Guidance -- Market Talk

14.08.2024 г., 09:02 ч. UTC

Пазарно говорене

Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk

18.07.2024 г., 11:55 ч. UTC

Печалби

Novartis Reports Near 40% Margin In Q2; Shares Slide -- IBD

18.07.2024 г., 09:40 ч. UTC

Пазарно говорене

Печалби

Novartis 2Q Results Seem Solid, Catalysts in Focus -- Market Talk

18.07.2024 г., 08:45 ч. UTC

Пазарно говорене

Печалби

Novartis Sales Beat Reflects Demand for New Drugs, Older Blockbusters Lag -- Market Talk

18.07.2024 г., 07:48 ч. UTC

Пазарно говорене

Novartis Prostate-Cancer Drug Pluvicto Sales Miss Raises Growth Questions -- Market Talk

18.07.2024 г., 07:01 ч. UTC

Пазарно говорене

Печалби

Novartis Profit Outlook Lift Reflects Blockbuster Drug Sales Boost, Operational Execution -- Market Talk

18.07.2024 г., 05:18 ч. UTC

Печалби

Correct: Novartis 2Q Core Operating Profit $4.95B

18.07.2024 г., 05:03 ч. UTC

Печалби

Novartis Had Seen Net Sales to Grow High-Single to Low Double-digit in 2024

18.07.2024 г., 05:03 ч. UTC

Печалби

Novartis Net Sales Guidance in 2024 Unchanged

18.07.2024 г., 05:03 ч. UTC

Печалби

Novartis Had Seen Core Operating Income to Grow Low Double-Digit to Mid-Teens in 2024

18.07.2024 г., 05:03 ч. UTC

Печалби

Novartis Expects Core Operating Income to Grow Mid- to High Teens in 2024

18.07.2024 г., 05:02 ч. UTC

Печалби

Novartis Raises 2024 Guidance

18.07.2024 г., 05:01 ч. UTC

Печалби

Analysts Had 2Q Core Operating Profit at $4.67B

18.07.2024 г., 05:01 ч. UTC

Печалби

Analysts Had 2Q Sales at $12.22B

18.07.2024 г., 05:01 ч. UTC

Печалби

Novartis 2Q Sales $12.51B

18.07.2024 г., 05:01 ч. UTC

Печалби

Novartis 2Q Core Operating Profit $12.51B

18.07.2024 г., 05:00 ч. UTC

Печалби

Novartis AG 2Q EPS $1.60

18.07.2024 г., 05:00 ч. UTC

Печалби

Novartis AG 2Q Adj EPS $1.97

18.07.2024 г., 05:00 ч. UTC

Печалби

Novartis AG 2Q Net Pft $3.2B

20.06.2024 г., 06:35 ч. UTC

Придобивния, сливания и поглъщания

MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q

20.06.2024 г., 06:34 ч. UTC

Придобивния, сливания и поглъщания

Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May

20.06.2024 г., 06:33 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders

20.06.2024 г., 06:32 ч. UTC

Придобивния, сливания и поглъщания

Novartis Holds Around 91.04% of MorphoSys as of Thursday

20.06.2024 г., 06:31 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders

Сравнение с други в отрасъла

Ценова промяна

Novartis AG Прогноза

Ценова цел

By TipRanks

0.35% нагоре

12-месечна прогноза

Среден 116.9 USD 0.35%

Висок 125 USD

Нисък 97 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Novartis AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Novartis AG през последните 3 месеца.

Техническа оценка

By Trading Central

116.33 / 119.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.